US2016008470A1PendingUtilityA1
Storage-stable compositions of glycerol monoalkyl ethers
Est. expiryJun 9, 2020(expired)· nominal 20-yr term from priority
A61Q 19/00A61K 8/347A61K 8/678A61K 2800/522A61P 17/00A61K 47/22A61K 47/183A61K 47/14A61K 8/42A61K 8/345A61Q 17/00A61K 8/676A61K 8/447A61K 47/10
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compositions which comprise a combination a) of one or more glycerol monoalkyl ether(s) of the general formula R—O—CH 2 —CHOH—CH 2 OH in which R is a branched or unbranched C3-C18-alkyl group, where the alkyl group can be substituted by one or more hydroxyl and/or C1-C4-alkoxy group(s) and/or the alkyl chain can be interrupted by up to four oxygen atoms, with b) an antioxidant or two or more antioxidants as stabilizer(s), the simultaneous presence of phosphocholines and phosphocholine derivatives being excluded.
Claims
exact text as granted — not AI-modified1 . A method to improve the long-term stabilization of a cosmetic or pharmaceutical composition, comprising adding to said cosmetic or pharmaceutical composition, a concentrate comprising from 95 to 99.999% by weight 3-[(2-ethylhexyl)oxy]-1,2-propanediol and an antioxidant in a weight ratio 3-[(2-ethylhexyl)oxy]-1,2-propanediol/antioxidant is in the range from 5,000:1 to 500:1 wherein said antioxidant is selected from the group consisting of Vitamin E, 3-tert-butyl-4-hydroxyanisole (BHA) and 2,6-tert-butyl-p-cresol (BHT) and mixtures thereof, such that said cosmetic or pharmaceutical composition is provided with 0.05% to 5% by weight of 3-[(2-ethylhexyl)oxy]-1,2-propanediol, and wherein a simultaneous presence of phosphocholine derivatives is excluded in said cosmetic or pharmaceutical composition.
2 . The method according to claim 1 , wherein said oxidant is Vitamin E.
3 . The method according to claim 1 , wherein said concentrate comprises from 99% to 99.99% by weight 3-[(2-ethylhexyl)oxy]-1,2-propanediol.
4 . The method according to claim 1 , wherein said cosmetic or pharmaceutical composition is provided with 0.1% to 1% by weight of 3-[(2-ethylhexyl)oxy]-1,2-propanediol.
5 . The method according to claim 1 , wherein said concentrate consists of from 95 to 99.999% by weight 3-[(2-ethylhexyl)oxy]-1,2-propanediol and an antioxidant in a weight ratio 3-[(2-ethylhexyl)oxy]-1,2-propanediol/antioxidant is in the range from 5,000:1 to 500:1 wherein said antioxidant is selected from the group consisting of Vitamin E, 3-tert-butyl-4-hydroxyanisole (BHA) and 2,6-tert-butyl-p-cresol (BHT) and mixtures thereof.
6 . The method according to claim 5 , wherein said oxidant is Vitamin E.
7 . The method according to claim 5 , wherein the proportion of 3-[(2-ethylhexyl) oxy]-1,2-propanediol in said concentrate is from 99% to 99.99% by weight.
8 . The method according to claim 5 , wherein the proportion of 3-[(2-ethylhexyl) oxy]-1,2-propanediol in said concentrate is from 99.5% to 99.95% by weight.
9 . The method according to claim 5 , wherein said cosmetic or pharmaceutical composition is provided with 0.1% to 1% by weight of 3-[(2-ethylhexyl)oxy]-1,2-propanediol.Join the waitlist — get patent alerts
Track US2016008470A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.